Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Quotes Basic TA News Snapshot
Total: 96 #1
CompanyViggle Inc.
IndustryGeneral Entertainment
Market Cap42.88MEPS (ttm)-16.71
P/E-EPS this Y76.60%
Forward P/E-EPS next Y-
PEG-EPS past 5Y40.70%
P/S2.13EPS next 5Y-
P/B1.42EPS Q/Q95.20%
Dividend-Sales Q/Q51.20%
Insider Own51.60%Inst Own20.40%
Insider Trans5.53%Inst Trans-0.84%
Short Float3.10%EarningsNov 12
Analyst Recom1.00Target Price12.00
Avg Volume886.55K52W Range1.27 - 56.00
Nov-21-14 01:04PMVIGGLE INC. Financials EDGAR Online Financials
Nov-19-14 08:00AMViggle Expands Rewards Offering To Include Movies and TV Shows Business Wire
Nov-18-14 08:42AMCan The Uptrend Continue for Viggle (VGGL)? Zacks
Nov-18-14 06:02AMStrength Seen in Viggle (VGGL): Stock Adds 19.9% in Session Zacks
Nov-17-14 07:06AMVIGGLE INC. Files SEC form 8-K, Other Events EDGAR Online
Nov-13-14 10:03AMViggle (VGGL) Stock Declines Today Following Wednesday's Surge at TheStreet
Nov-13-14 08:45AMViggle Making Social Television a Rewarding Proposition: Analyst Report & Valuation by Small Cap IR PR Newswire
Nov-12-14 11:52AMViggle (VGGL) Stock Rising Today After Revenue Jumps 49% at TheStreet
Nov-12-14 08:46AMVIGGLE INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
Nov-12-14 08:00AMViggle Reports 49% Year-Over-Year Revenue Growth and 112% Increase in Registered Users Business Wire
Viggle Inc. operates as a mobile and Web-based entertainment marketing platform for media companies, brands, and consumers in the United States. It guides users towards various forms of media consumption with television enhancement, music discovery, entertainment content publishing, and distributed viewing reminders. The company allows its consumers to play TV shows, share comments through social media, answer trivia questions or polls, chat with friends, play games, or discover more about the show, while watching TV through a free application that works on various types of mobile phones and tablets. Its users receive points for each check-in and engagement, such as poll, video quiz, game, or slide show and could redeem the points within the rewards catalog for items, including deals and offers, products, sweepstakes, charitable donations, select retail gift cards, and Viggle-branded and other merchandise. Viggle Inc., through its, reports news stories and publishes information content covering top television shows, music, celebrities, entertainment news, and fashion. The company was formerly known as Function(x) Inc. and changed its name to Viggle Inc. in May 2012. Viggle Inc. was incorporated in 1994 and is headquartered in New York, New York.
CompanyBio Blast Pharma Ltd.
Market Cap51.84MEPS (ttm)-0.27
P/E-EPS this Y-
Forward P/E-EPS next Y-189.50%
PEG-EPS past 5Y0.00%
P/S-EPS next 5Y-
P/B13.43EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float0.00%Earnings-
Analyst Recom1.50Target Price23.50
Avg Volume25.11K52W Range4.50 - 11.00
Nov-26-14 02:03PMNasdaq stocks posting largest percentage increases AP
Nov-21-14 08:00AMBio Blast Pharma Reports Third Quarter Financial Results GlobeNewswire
Nov-19-14 09:00AMBio Blast Pharma Receives Orphan Drug Designation From U.S. FDA for Cabaletta for the Treatment of Spinocerebellar Ataxia Type 3 GlobeNewswire
Sep-22-14 08:00AMBio Blast Pharma Announces Initiation of Its Canadian OPMD Clinical Study Center at McGill University, Montreal GlobeNewswire
Sep-17-14 08:00AMBioBlast Pharma Announces Preclinical and Clinical Pharmacokinetic Results With Cabaletta, Interim Safety Results From Phase 2/3 HOPEMD Study in OPMD GlobeNewswire
Sep-08-14 10:00AMBio Blast Pharma Ltd. (NASDAQ: ORPN) to Ring The NASDAQ Stock Market Opening Bell GlobeNewswire
Sep-08-14 08:00AMBioBlast to Ring the NASDAQ Stock Market Opening Bell GlobeNewswire
Aug-29-14 08:00AMBioBlast Pharma Reports Second Quarter Financial Results GlobeNewswire
Aug-04-14 12:17PMIPO Outlook: Can A $200 Million IPO Be The Answer After A Lackluster Week? Benzinga
Aug-01-14 10:51AM[video] IPO expectations not met at CNBC
Bio Blast Pharma Ltd., a clinical-stage biotechnology company, develops therapies for patients with rare and ultra-rare genetic diseases. Its products include Cabaletta, a mutant protein stabilizing platform based on a small repurposed molecule to treat oculopharyngeal muscular dystrophy, Machado Joseph disease or SCA3, and Kennedy's disease or SBMA; and BBrm, a read-through platform based on a small repurposed molecule that enables the read-through (or bypassing) of genetic defects called nonsense mutations or stop codons that interfere with normal protein formation to treat diseases caused by nonsense mutation. The company's products also comprise mPRT, a mitochondrial protein replacement platform based on biological fusion proteins to treat mitochondrial protein deficiency diseases (Friedrich's Ataxia and ornithine transcarbamylase deficiency) by replacing missing or mutated proteins into mitochondria, and restoring cell function. Bio Blast Pharma Ltd. was founded in 2012 and is headquartered in Tel Aviv, Israel.
CompanyMecox Lane Limited
IndustrySpecialty Retail, Other
Market Cap41.02MEPS (ttm)-1.72
P/E-EPS this Y77.00%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-26.10%
P/S0.55EPS next 5Y-
P/B0.81EPS Q/Q-45.50%
Dividend-Sales Q/Q12.00%
Insider Own8.80%Inst Own1.30%
Insider Trans-Inst Trans0.60%
Short Float-EarningsMar 03
Analyst Recom-Target Price5.00
Avg Volume11.85K52W Range3.05 - 5.78
Nov-25-14 04:01PMMecox Lane Limited Announces Third Quarter 2014 Results GlobeNewswire
Nov-18-14 06:08AMMecox Lane Limited to Announce Third Quarter Results on November 25, 2014 GlobeNewswire
Sep-18-14 04:01PMMecox Lane Limited Announces Second Quarter 2014 Results GlobeNewswire
Sep-18-14 04:01PMMecox Lane Limited Completes Spin-Off of Apparel and Accessories Business GlobeNewswire
Sep-15-14 04:00AMMecox Lane Limited to Announce Second Quarter Results on September 18 GlobeNewswire
Jul-25-14 04:01PM3 Stocks Pushing The Specialty Retail Industry Lower at TheStreet
Jul-21-14 02:19AMHouse Of Fraser's Chinese Buyer Transfers Funds For Purchase at Forbes
Apr-16-14 01:04PMMECOX LANE LTD Financials EDGAR Online Financials
Mar-04-14 09:02PMMecox Lane's CEO Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
Jan-30-14 06:00AMMecox Lane announces investment by Cnshangquan E-Commerce
Mecox Lane Limited designs and sells health and beauty products through various retail channels in the People's Republic of China. It offers beauty and healthcare products, including skin care, fragrance, cosmetics, and other personal care products. The company sells its products through its online platform and stores. The company was founded in 1996 and is headquartered in Shanghai, the People's Republic of China. As of May 20, 2014, Mecox Lane Limited operates as a subsidiary of Cnshangquan E-Commerce Co., Ltd.
CompanyCoronado Biosciences, Inc.
Market Cap90.84MEPS (ttm)-0.74
P/E-EPS this Y4.70%
Forward P/E-EPS next Y13.60%
PEG-EPS past 5Y-42.20%
P/S-EPS next 5Y26.20%
P/B1.07EPS Q/Q45.80%
Dividend-Sales Q/Q-
Insider Own26.70%Inst Own17.70%
Insider Trans11.08%Inst Trans-16.21%
Short Float12.98%EarningsAug 07
Analyst Recom3.50Target Price1.50
Avg Volume171.90K52W Range1.45 - 3.31
Nov-25-14 06:18AMCoronado Biosciences (CNDO) Jumps: Stock Rises 8.5% Zacks
Nov-24-14 01:00PMWarren Buffett Pick CBI Tumbles On Rating Downgrade at TheStreet
Nov-15-14 01:04PMCORONADO BIOSCIENCES INC Financials EDGAR Online Financials
Nov-11-14 02:06PMRackspace Bounces, Making Dan Loeb $34 Million In The Process at TheStreet
Nov-10-14 04:15PMCORONADO BIOSCIENCES INC Files SEC form 8-K, Unregistered Sale of Equity Securities, Financial Statements and Exhibit EDGAR Online
Nov-07-14 08:30AMCoronado Biosciences Raises $3,500,000 Through the Private Placement of Restricted Common Stock GlobeNewswire
Nov-07-14 06:02AMCORONADO BIOSCIENCES INC Files SEC form 8-K, Other Events EDGAR Online
Nov-06-14 07:21AMCORONADO BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
Nov-06-14 07:00AMCoronado Biosciences Reports Financial Results GlobeNewswire
Oct-08-14 08:30AMCoronado Biosciences Forms Subsidiary to Acquire and License Dermatology Products for Commercialization GlobeNewswire
Coronado Biosciences, Inc., a development stage biopharmaceutical company, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. The company's principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201, a biologic comprising the microscopic eggs of the porcine whipworm for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis, multiple sclerosis, autism, psoriasis, and type 1 diabetes; and CNDO-109, a biologic that activates the immune system's natural killer cells to seek and destroy cancer cells for the treatment of acute myeloid leukemia. Coronado Biosciences, Inc. has strategic alliances and commercial agreements with Ovamed GmbH, Dr. Falk Pharma GmbH, Freie Universitt Berlin, UCL Business PCL, and Progenitor Cell Therapy. The company was founded in 2006 and is based in Burlington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROSENWALD LINDSAY A MDPresident and CEONov 06Buy1.61150,000241,5004,790,347Nov 10 04:19 PM
Hoenlein MalcolmDirectorNov 06Buy1.6125,00040,25055,000Nov 10 04:23 PM
WEISS MICHAEL SExec. VC - Strategic Dev.Nov 06Buy1.611,000,0001,610,0006,938,038Nov 10 04:25 PM
Lu LucyChief Financial OfficerJun 02Buy1.375,0006,85030,631Jun 04 04:55 PM
HORGAN KEVINFormer Chief Medical OfficerApr 22Option Exercise1.7147,56681,33847,566Apr 23 04:45 PM
CompanyuniQure N.V.
Market Cap219.88MEPS (ttm)-3.28
P/E-EPS this Y-184.30%
Forward P/E-EPS next Y25.50%
PEG-EPS past 5Y0.00%
P/S37.91EPS next 5Y-
P/B3.22EPS Q/Q36.40%
Dividend-Sales Q/Q44.40%
Insider Own-Inst Own73.20%
Insider Trans-Inst Trans0.26%
Short Float0.37%Earnings-
Analyst Recom1.30Target Price28.33
Avg Volume24.98K52W Range8.29 - 18.75
Nov-26-14 07:33AMUniqure (QURE) Shares March Higher, Can It Continue? Zacks
Nov-21-14 09:33AMuniQure to Host Investor Day in New York City GlobeNewswire
Nov-10-14 05:03AMuniQure to Present at Jefferies Global Healthcare Conference - London GlobeNewswire
Oct-27-14 06:45AMAIPGENE Consortium Presents 1 Year Follow-Up Clinical Data from Acute Intermittent Porphyria Phase I Clinical Trial Using AAV5-PBGD Gene Therapy Candidate GlobeNewswire
Sep-25-14 09:08AMuniQure to Present at the Leerink Partners Rare Disease Roundtable Conference GlobeNewswire
Sep-02-14 05:41AMuniQure Announces Results for the Second Quarter and First Half of 2014 and Provides Update on Gene Therapy Programs GlobeNewswire
Aug-20-14 08:30AMCan the Rally in Uniqure (QURE) Shares Continue? Zacks
Jun-23-14 07:52AMBayer bets on gene therapy with Dimension deal Reuters
Jun-23-14 07:36AMBayer bets on gene therapy for haemophilia with Dimension deal Reuters
Jun-18-14 09:26AMuniQure and Medison Sign Glybera Distribution Agreement for Israel PR Newswire
uniQure BV, a biopharmaceutical company, develops gene therapies through its modular technology platform for the treatment of genetic or acquired diseases. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency, an orphan metabolic disease. It also develops a pipeline of additional adeno-associated virus (AAV) based gene therapies, including AMT-060, a gene therapy for the treatment of hemophilia B; AMT-021 for acute intermittent porphyria; AMT-110 for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease, as well as various programs that are in early preclinical development stage. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, and University of California San Francisco. uniQure BV was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
TickerNRX [NASD]
CompanyNephroGenex, Inc.
IndustryDrugs - Generic
Market Cap35.88MEPS (ttm)-1.77
P/E-EPS this Y-115.20%
Forward P/E-EPS next Y12.60%
PEG-EPS past 5Y0.00%
P/S-EPS next 5Y-
P/B1.26EPS Q/Q-108.30%
Dividend-Sales Q/Q-
Insider Own55.86%Inst Own72.00%
Insider Trans-Inst Trans-0.25%
Short Float0.06%EarningsNov 13
Analyst Recom2.00Target Price25.00
Avg Volume15.15K52W Range3.96 - 13.00
Nov-21-14 01:04PMNEPHROGENEX, INC. Financials EDGAR Online Financials
Nov-20-14 04:48PMNEPHROGENEX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obli EDGAR Online
Nov-20-14 04:05PMNephroGenex Announces Closing of $12 Million Term Loan Facility Business Wire
Nov-13-14 07:07AMQ3 2014 NephroGenex Inc Earnings Release - Time Not Supplied CCBN
Nov-13-14 07:00AMNephroGenex, Inc. Announces Presentation at the American Society of Nephrologys Kidney Week 2014 Business Wire
Nov-12-14 04:12PMNephroGenex Reports Third Quarter 2014 Financial Results Business Wire
Nov-12-14 04:05PMNEPHROGENEX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit EDGAR Online
Nov-03-14 08:00AMNephroGenex Announces Date of Conference Call to Discuss Third Quarter 2014 Financial Results Business Wire
Oct-31-14 08:00AMNephroGenex to Participate in Two Healthcare Conferences in November Business Wire
Oct-01-14 06:37AMNephroGenex Appoints Marco Taglietti, M.D. to Board of Directors Business Wire
NephroGenex, Inc., a pharmaceutical company, focuses on developing therapeutics to treat kidney disease. The company develops Pyridorin (pyridoxamine dihydrochloride), a therapeutic agent to slow the progression of diabetic nephropathy. It is also involved in studying the application of an intravenous formulation of Pyridorin for the treatment of specific types of acute kidney injury where pathogenic oxidative chemistries have been identified as a contributing factor to the severity of this condition. NephroGenex, Inc. was founded in 2004 and is headquartered in Research Triangle Park, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Peterson BobVP of Prod. Dev. & Reg. Aff's.Nov 25Buy4.202,0008,4002,000Nov 25 04:07 PM
CompanyE2open, Inc.
IndustryApplication Software
Market Cap181.10MEPS (ttm)-1.08
P/E-EPS this Y-9.30%
Forward P/E-EPS next Y28.80%
PEG-EPS past 5Y30.90%
P/S2.36EPS next 5Y20.00%
P/B3.44EPS Q/Q-39.10%
Dividend-Sales Q/Q11.10%
Insider Own0.70%Inst Own86.30%
Insider Trans-75.79%Inst Trans-1.34%
Short Float11.52%EarningsOct 08/a
Analyst Recom2.40Target Price11.00
Avg Volume382.05K52W Range5.31 - 29.82
Nov-26-14 02:03PMNasdaq stocks posting largest percentage increases AP
Nov-26-14 12:59PMVeeva Systems Gets A Boost On Earnings at TheStreet
Nov-20-14 08:59AME2open Earns Drummond Certification in Fall 2014 AS2 Interoperability Test Event PR Newswire
Nov-05-14 09:00AME2open to Present at November 2014 OAGi Plenary Meeting PR Newswire
Oct-16-14 09:00AME2open to Discuss New Product Introduction and S&OP Strategies at the 2014 Consumer Goods Business and Technology Leadership Conference PR Newswire
Oct-16-14 07:14AMShould You Get Rid of E2open (EOPN) Now? Zacks
Oct-15-14 01:04PME2OPEN INC Financials EDGAR Online Financials
Oct-08-14 04:52PMWhy E2open (EOPN) Stock Is Down in After-Hours Trading Today at TheStreet
Oct-08-14 04:18PME2Open Falls 11%: FYQ2 Beats; Q3, Year Views Light at
Oct-08-14 04:08PME2OPEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
E2open, Inc. provides cloud-based, on-demand software solutions for supply chain management. The company delivers its software solutions on an integrated platform that enables companies to collaborate with their trading partners to procure, manufacture, sell, and distribute products. The company's E2open Business Network enables its customers to share product information, forecasts, inventory positions, sales orders, purchase orders, manufacturing work orders, quality and environmental data, shipments, invoices, and payments with their trading partners. Its products and services include E2 Analytics, which provides real-time data related to transformation, aggregation, and loading of standard business intelligence processes; E2 Planning & Response: Rapid Optimization that provide periodic, batch planning capabilities for network requirements planning and for network constrained planning; and E2 Planning & Response: Rapid Resolutions, which provides response planning capabilities so when change occurs planners can utilize what-if scenario planning to resolve demand and/or supply exceptions, as well as simulate events, such as promotions, new product introduction, and network changes. The company also offers E2 Process Management, a multi-enterprise software for demand, multi-tier, and supply processes; and E2 Cloud Connectivity, a multi-enterprise software for B2B integration that allows enterprises to integrate their internal applications and the applications of their trading partners through its E2open Business Network. In addition, it offers professional services, such as consulting, solution deployment, and B2B on-boarding services. The company sells its solutions directly, as well as through resellers and integrators primarily in the Americas, Europe, and Asia. It has a strategic alliance agreement with KPMG LLP. The company was founded in 2000 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MALONEY PETER JChief Financial OfficerOct 09Option Exercise0.0012,375098,161Oct 10 05:50 PM
Schoenthaler RobertChief Customer OfficerOct 09Option Exercise0.0012,375014,873Oct 10 05:54 PM
WOODWARD MARKPresident & CEOOct 09Option Exercise0.0017,900095,249Oct 10 05:58 PM
Packer David WChief Sales OfficerSep 03Option Exercise0.004,00004,000Sep 03 06:28 PM
Schoenthaler RobertChief Customer OfficerSep 03Option Exercise0.004,00004,000Sep 03 06:33 PM
CompanyRXi Pharmaceuticals Corporation
Market Cap39.74MEPS (ttm)-1.03
P/E-EPS this Y48.80%
Forward P/E-EPS next Y1.10%
PEG-EPS past 5Y0.00%
P/S245.33EPS next 5Y-
P/B14.46EPS Q/Q43.30%
Dividend-Sales Q/Q-94.70%
Insider Own6.00%Inst Own9.00%
Insider Trans2.67%Inst Trans6.08%
Short Float3.70%Earnings-
Analyst Recom2.00Target Price10.17
Avg Volume490.00K52W Range1.64 - 6.84
Nov-21-14 01:04PMRXI PHARMACEUTICALS CORP Financials EDGAR Online Financials
Nov-13-14 07:21AMRXI PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
Nov-13-14 07:10AMRXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2014 PR Newswire
Nov-13-14 07:02AMRXI PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
Oct-07-14 07:02AMRXi Pharmaceuticals to Present New Data in its First Phase 2a Clinical Trial with RXI-109 PR Newswire
Sep-29-14 07:02AMRXi Pharmaceuticals to Present at the 13th Annual BIO Investor Forum PR Newswire
Sep-17-14 07:02AMRXi Pharmaceuticals Strengthens Intellectual Property Portfolio PR Newswire
Sep-11-14 07:02AMRXi Pharmaceuticals Presented an Update on the Company's Dermatology and Ophthalmology Franchises PR Newswire
Sep-03-14 08:43AMRXi Pharmaceuticals (RXII) Jumps: Stock Moves 11.4% Higher Zacks
Sep-03-14 07:02AMRXi Pharmaceuticals to Present at the Rodman & Renshaw 16th Annual Global Investment Conference PR Newswire
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering, developing, and commercializing therapies based on its proprietary, next-generation RNA interference (RNAi) platform. The company's lead product candidate, RXI-109, is a self-delivering RNAi compound, which is in Phase II clinical trial for use in the reduction of dermal scarring. Its therapeutic development programs in the discovery and preclinical stages include products for the treatment of ocular scarring, liver fibrosis, joint fibrosis, and vascular restenosis. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CAUWENBERGH GEERTPresident & CEOOct 13Buy1.683,0005,04044,000Oct 14 09:36 AM
CAUWENBERGH GEERTPresident & CEOSep 19Buy2.204,5009,9004,500Sep 23 01:21 PM
CAUWENBERGH GEERTPresident & CEOSep 16Buy2.085,00010,39046,000Sep 16 03:31 PM
CAUWENBERGH GEERTPresident & CEOSep 15Buy2.1810,00021,84941,000Sep 15 12:46 PM
CompanyHong Kong Television Network Limited
CountryHong Kong
IndustryBroadcasting - TV
Market Cap404.01MEPS (ttm)-0.52
P/E-EPS this Y48.00%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-17.80%
P/S2020.04EPS next 5Y-
P/B0.99EPS Q/Q-271.40%
Dividend-Sales Q/Q-50.00%
Insider Own-Inst Own3.70%
Insider Trans-Inst Trans-1.65%
Short Float0.42%Earnings-
Analyst Recom-Target Price-
Avg Volume43.30K52W Range5.00 - 11.83
Jan-10-14 01:04PMHONG KONG TELEVISION NETWORK LTD Financials EDGAR Online Financials
Hong Kong Television Network Limited is engaged in multimedia production and contents distribution, and other multimedia related activities in Hong Kong. The company produces dramas, variety and infotainment, and purchased content programs. It is also involved in the property investment activities; production, publishing, and licensing of musical works; and provision of management and agency services to artistes. The company was formerly known as City Telecom (H.K.) Limited and changed its name to Hong Kong Television Network Limited in January 2013. Hong Kong Television Network Limited was founded in 1992 and is headquartered in Kwai Chung, Hong Kong.
CompanyRigel Pharmaceuticals, Inc.
IndustryDrugs - Generic
Market Cap177.32MEPS (ttm)-0.98
P/E-EPS this Y22.70%
Forward P/E-EPS next Y-13.10%
PEG-EPS past 5Y22.60%
P/S30.57EPS next 5Y-
P/B1.21EPS Q/Q11.10%
Dividend-Sales Q/Q-
Insider Own0.10%Inst Own90.90%
Insider Trans-18.56%Inst Trans1.86%
Short Float3.09%EarningsAug 05/b
Analyst Recom2.60Target Price6.50
Avg Volume598.76K52W Range1.56 - 5.00
Nov-24-14 04:16PMRIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh EDGAR Online
Nov-24-14 07:32AM7:32 am Rigel Pharma announces retirement of CEO; Raul Rodriguez named CEO and appointed to the Board, Gary Lyons named Chairman
Nov-24-14 07:30AMRigel Announces Executive Management Changes PR Newswire
Nov-14-14 01:04PMRIGEL PHARMACEUTICALS INC Financials EDGAR Online Financials
Nov-06-14 07:08PM10-Q for Rigel Pharmaceuticals, Inc. Company Spotlight
Nov-04-14 04:20PMRIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
Nov-04-14 01:47PMRIGEL PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Nov-04-14 09:37AMRigel posts 3Q loss AP
Nov-04-14 07:30AMRigel Announces Third Quarter 2014 Financial Results PR Newswire
Aug-14-14 02:30PMRigel's R348 Fails in Phase II Study, Shares Down 13.6% Zacks
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor that intends to enter Phase III clinical trials for immune thrombocytopenic purpura and a Phase II clinical trial for immunoglobulin A nephropathy; R348, a topical janus kinase/SYK inhibitor in Phase II clinical trials for the treatment of keratoconjunctivitis sicca or chronic dry eye; R118, an adenosine monophosphate-activated protein kinase activator that intends to enter Phase I clinical trial; and two oncology product candidates in Phase I development. It also has small molecule discovery programs in muscle wasting. Rigel Pharmaceuticals, Inc. has collaboration agreement Daiichi Sankyo to pursue research related to a specific target from a class of drug targets called ligases that control cancer cell proliferation through protein degradation; and a license agreement with BerGenBio AS for the development and commercialization of an oncology program. The company was founded in 1996 and is based in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PAYAN DONALD GEVP, Pres. Discovery&ResearchSep 03Sale2.5620,00051,20068,334Sep 05 06:07 PM
PAYAN DONALD GEVP, Pres. Discovery&ResearchFeb 24Sale3.7120,00074,23888,334Feb 26 07:21 PM
1 2 3 4 5 6 7 8 9 10 next